EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis

Rui Feng, Liman Huo, Yun-Feng Diao, Yajing Wang, Mei Zhou, Ying Zheng, Qi Lv

Frontiers in Pharmacology · 30.06.2026 · 17

DOI: 10.3389/fphar.2026.1860312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.06.2026. Verfasst von Rui Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Disaster and Emergency Medicine, Tianjin University, Tianjin, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab plus ipilimumab has demonstrated survival benefits as first-line therapy for unresectable hepatocellular carcinoma (HCC). However, the high treatment cost may limit its economic value in China. This study evaluated the cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable HCC from the perspective of the Chinese healthcare system.

Methods

A partitioned survival model (PSM) with progression-free survival (PFS), progressed disease (PD), and death health states was developed over a 10-year time horizon. Clinical data were obtained from the phase III CheckMate 9DW trial. Overall survival (OS) and PFS data were reconstructed from published Kaplan–Meier curves and extrapolated using alternative parametric and flexible survival models. Model selection was based on statistical fit, visual inspection, and clinical plausibility. Structural uncertainty was explored through 625 survival model combinations and multiple scenario analyses involving time horizons, post-progression treatment, treatment exposure, adverse event (AE) management, utility values, and non-drug medical costs. Threshold and price–willingness-to-pay (WTP) analyses were conducted to evaluate the impact of treatment price reductions on cost-effectiveness outcomes.

Results

In the base-case analysis, nivolumab plus ipilimumab increased total costs (USD 162,437.52 vs. USD 81,990.70) and quality-adjusted life years (QALYs) (1.89 vs. 1.40), resulting in an incremental cost-effectiveness ratio (ICER) of USD 164,177.18/QALY, substantially exceeding the Chinese WTP threshold of USD 28,972.38/QALY. Across all 625 survival model combinations and scenario analyses, ICERs consistently remained above the predefined WTP threshold. Scenario analyses demonstrated that the economic conclusions were generally robust to alternative assumptions regarding survival extrapolation, utility inputs, downstream treatment, treatment exposure, and healthcare costs. Price-threshold analyses indicated that an approximate 67% reduction in treatment cost would be required for nivolumab plus ipilimumab to reach the conventional Chinese WTP threshold.

Conclusion

At current prices, nivolumab plus ipilimumab is unlikely to be cost-effective as a first-line treatment for unresectable HCC in China. This conclusion remained consistent across extensive structural and parameter uncertainty analyses. Substantial price reductions may be required to improve the economic value of dual immunotherapy in the Chinese healthcare setting.

Schlagwörter

Stichwörter der Autor:innen

cost-effectiveness analysiseconomic evaluationhepatocellular carcinomaimmune checkpoint inhibitorspartitioned survival modelthreshold analysis

Autor:innen und Institutionen

  • School of Disaster and Emergency Medicine, Tianjin University, Tianjin, China.
  • Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Institute of Traumatic Brain Injury and Neurology, Characteristic Medical Center of PAPF, Tianjin, China.

Zitieren

APA

Feng, R., Huo, L., Diao, Y. F., Wang, Y., Zhou, M., Zheng, Y., & Lv, Q. (2026). Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1860312

Vancouver

Feng R, Huo L, Diao YF, Wang Y, Zhou M, Zheng Y, et al. Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1860312

BibTeX
@article{Feng2026,
  author = {Feng, Rui and Huo, Liman and Diao, Yun-Feng and Wang, Yajing and Zhou, Mei and Zheng, Ying and Lv, Qi},
  title = {Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1860312}
}
Kostenlos starten →